{"article_title": "The next big breakout?", "article_keywords": ["underperform", "power", "biotech", "big", "somaiya", "topic", "talking", "breakout", "worst", "election", "tabak", "strategist"], "article_url": "http://www.cnbc.com/2016/04/07/biotech-the-next-big-breakout.html", "article_text": "\"A lot of this had to do with the Allergan-Pfizer deal falling down and the Allergan CEO talking about other purchases they might make,\" Maley, an equity strategist at Miller Tabak, said Thursday on CNBC's \"Power Lunch.\"\n\nAnalysts also have been looking at the effect the past five election cycles have had on biotech, according to Somaiya, an analyst at BMO.\n\n\"If you go back to the 2008 election cycle when health-care reform was such a hot topic and, obviously the follow-through was Obamacare, the group did underperform and it was probably the worst period for the Nasdaq biotech index,\" he said on \"Power Lunch.\"", "article_metadata": {"AssetType": "cnbcnewsstory", "description": "Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's \"Power Lunch.\"", "author": "Josh Weiss", "og": {"site_name": "CNBC", "description": "Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's \"Power Lunch.\"", "title": "Biotech: Breakout or lull?", "url": "http://www.cnbc.com/2016/04/07/biotech-the-next-big-breakout.html", "image": "http://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2014/06/24/101785842-476084819.1910x1000.jpg", "type": "article"}, "twitter": {"description": "Is the biotech industry having a good year or a slow one? Expert analysts weigh in on CNBC's \"Power Lunch.\"", "title": "Biotech: The next big breakout?", "url": "http://www.cnbc.com/2016/04/07/biotech-the-next-big-breakout.html", "image": {"src": "http://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2014/06/24/101785842-476084819.1910x1000.jpg"}, "creator": "@CNBC", "site": "@CNBC", "card": "summary_large_image"}, "al": {"ios": {"app_name": "CNBC Business News and Finance", "app_store_id": 398018310}}, "apple-itunes-app": "app-id=398018310", "GOOGLEBOT": "unavailable_after: 31 Dec 9999 23:59:59 GMT", "keywords": "Biotech and Pharmaceuticals, Biotech and Pharmaceuticals, Equipment and Services, Health Care IT, Health Care, Health Insurance, Life, Business, Power Lunch, Obamacare, Allergan plc, NASDAQ Biotechnology Index, business news", "article": {"publisher": "https://www.facebook.com/cnbc", "published_time": "2016-04-07T19:01:38-0400", "author": "https://www.facebook.com/CNBC", "section": "Biotech and Pharmaceuticals", "modified_time": "2016-04-07T19:02:24-0400", "tag": "NASDAQ Biotechnology Index"}, "pageNodeId": 103530466, "news_keywords": "Biotech, healthcare reform, pharma, markets, health, Obamacare, Power Lunch, biotech ETF"}, "article_summary": "Analysts also have been looking at the effect the past five election cycles have had on biotech, according to Somaiya, an analyst at BMO.\n\"A lot of this had to do with the Allergan-Pfizer deal falling down and the Allergan CEO talking about other purchases they might make,\" Maley, an equity strategist at Miller Tabak, said Thursday on CNBC's \"Power Lunch.\"\n\"If you go back to the 2008 election cycle when health-care reform was such a hot topic and, obviously the follow-through was Obamacare, the group did underperform and it was probably the worst period for the Nasdaq biotech index,\" he said on \"Power Lunch.\""}